Robert F Kennedy Jr faced pointed questioning during his nomination hearing for secretary of health and human services, as lawmakers sought to reconcile his past controversial statements with the more ...

Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it ...

Privately-held Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial ...

The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio. The expansion is fueled by increased ...

Evaxion Biotech has priced a public offering, seeking to raise $10.8 million before expenses, with closing anticipated tomorrow.

US public health officials have been ordered to immediately suspend all collaboration with the World Health Organization (WHO ...

New US President Donald Trump and his administration have confirmed that lowering the cost of prescription drugs for Americans is a top priority, suggesting that they will continue the work of the ...

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of a Phase IIb trial being met. The data, which include a positive safety ...

US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

Danish CNS specialist Lundbeck announced positive results from the 12-month open-label extension of the Phase Ib/IIa PACIFIC trial, evaluating bexicaserin in participants aged 12-65 with developmental ...